GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » Cyclically Adjusted PB Ratio

Theratechnologies (Theratechnologies) Cyclically Adjusted PB Ratio : 1.44 (As of Jun. 09, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Theratechnologies's current share price is $1.22. Theratechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 was $0.85. Theratechnologies's Cyclically Adjusted PB Ratio for today is 1.44.

The historical rank and industry rank for Theratechnologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

THTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.17   Med: 6.05   Max: 25.79
Current: 1.47

During the past years, Theratechnologies's highest Cyclically Adjusted PB Ratio was 25.79. The lowest was 0.17. And the median was 6.05.

THTX's Cyclically Adjusted PB Ratio is ranked better than
53.71% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs THTX: 1.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Theratechnologies's adjusted book value per share data for the three months ended in Feb. 2024 was $-0.535. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.85 for the trailing ten years ended in Feb. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Theratechnologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Theratechnologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Cyclically Adjusted PB Ratio Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.20 6.74 9.89 7.60 1.75

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.56 3.51 0.97 1.75 1.70

Competitive Comparison of Theratechnologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Theratechnologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Cyclically Adjusted PB Ratio falls into.



Theratechnologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Theratechnologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.22/0.85
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theratechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, Theratechnologies's adjusted Book Value per Share data for the three months ended in Feb. 2024 was:

Adj_Book=Book Value per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.535/125.4675*125.4675
=-0.535

Current CPI (Feb. 2024) = 125.4675.

Theratechnologies Quarterly Data

Book Value per Share CPI Adj_Book
201405 0.961 99.394 1.213
201408 0.693 99.315 0.875
201411 0.450 99.078 0.570
201502 0.398 99.078 0.504
201505 0.443 100.263 0.554
201508 0.884 100.579 1.103
201511 0.913 100.421 1.141
201602 0.908 100.421 1.134
201605 1.146 101.765 1.413
201608 1.196 101.686 1.476
201611 1.213 101.607 1.498
201702 1.692 102.476 2.072
201705 1.811 103.108 2.204
201708 1.931 103.108 2.350
201711 1.785 103.740 2.159
201802 1.688 104.688 2.023
201805 1.586 105.399 1.888
201808 1.863 106.031 2.205
201811 1.822 105.478 2.167
201902 1.775 106.268 2.096
201905 1.630 107.927 1.895
201908 1.561 108.085 1.812
201911 1.291 107.769 1.503
202002 1.074 108.559 1.241
202005 0.801 107.532 0.935
202008 0.443 108.243 0.513
202011 0.167 108.796 0.193
202102 1.722 109.745 1.969
202105 1.481 111.404 1.668
202108 1.130 112.668 1.258
202111 0.747 113.932 0.823
202202 0.427 115.986 0.462
202205 -0.490 120.016 -0.512
202208 -0.759 120.569 -0.790
202211 -0.933 121.675 -0.962
202302 -1.335 122.070 -1.372
202305 -1.716 124.045 -1.736
202308 -1.723 125.389 -1.724
202311 -0.454 125.468 -0.454
202402 -0.535 125.468 -0.535

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theratechnologies  (NAS:THTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Theratechnologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.